Emergent BioSolutions’ Investigational Anthrax Vaccine, NuThrax, Granted Fast Track Designation

ROCKVILLE, Md., Jun 09, 2011 — Emergent BioSolutions Inc. (NYSE:EBS) announced today that its investigational anthrax vaccine, NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The vaccine candidate, also known as AV7909, consists of BioThrax(R) (Anthrax Vaccine Adsorbed) in combination with [...]

June 10, 2011  Tags: , , , ,   Posted in: Chief executive officer, Emergent BioSolutions, NuThrax, US Food and Drug Administration., fuad el-hibri  No Comments

Emergent BioSolutions on Track to Complete Delivery of 14.5M Doses of BioThrax to the US Government Ahead of Schedule

ROCKVILLE, Md., May 31, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that eight lots of BioThrax(R) (Anthrax Vaccine Adsorbed) have received regulatory release for delivery to the U.S. government under the company’s contract (200-2009-30162) originally written to supply 14.5 million doses of BioThrax to the Strategic National Stockpile. This marks the largest [...]

June 7, 2011  Tags: , , , , ,   Posted in: Biothrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, US Food and Drug Administration., fuad el-hibri  No Comments

Emergent BioSolutions to Present at Jefferies 2011 Global Healthcare Conference

ROCKVILLE, Md., May 25, 2011 — Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the Jefferies 2011 Global Healthcare Conference in New York on Tuesday, June 7, 2011 at 1:15 PM Eastern. During the presentation, a member of the company’s senior management team will provide a corporate [...]

June 1, 2011  Tags: , , , , ,   Posted in: Business, El-Hibri, Financial Performance, Healthcare Conference, Investors, fuad el-hibri  No Comments

Emergent BioSolutions Reports Financial Results for First Quarter 2011

ROCKVILLE, Md., May 05, 2011 (BUSINESS WIRE) — Emergent BioSolutionsInc. (NYSE: EBS) announced  its financial results for the first quarter ended March 31, 2011.
For 1Q 2011, total revenues were $18.5 million as compared to $46.8 million in 2010. In addition, for 1Q 2011 the company recorded a net loss of $21.4 million, or $0.61 per [...]

May 12, 2011  Tags: , , , , ,   Posted in: BioDefense, Biothrax, Business, Chief executive officer, Chief financial officer, Revenue  No Comments

Emergent BioSolutions to Present Today at Needham & Company Healthcare Conference

Emergent BioSolutions Inc. (NYSE: EBS) will be webcasting its presentation at the 10th Annual Needham & Company Healthcare Conference in New York on Tuesday, April 5, 2011 at 8:00 AM Eastern. During the presentation, a member of the company’s senior management team will provide a corporate overview, which may include a discussion of [...]

April 5, 2011  Tags: , , , ,   Posted in: Board of Directors, El-Hibri, Emergent BioSolutions, Healthcare Conference, fuad, fuad el-hibri  No Comments

Emergent BioSolutions Observes World TB Day Launches “OETC: Endeavor to End Tuberculosis,” a video to raise public awareness of TB

ROCKVILLE, Md., Mar 24, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today released the following statement in observance of  World TB Day.
The World TB Day 2011 campaign, “On the move against TB: Transforming the fight towards elimination,” challenges us to undertake the fight [...]

March 25, 2011  Tags: , , , ,   Posted in: Emergent BioSolutions, TB, World TB Day, fuad, fuad el-hibri  No Comments

Emergent BioSolutions Presents Positive Data from Its TRU-016 Program at American Society of Hematology Meeting

ROCKVILLE, Md., Dec 06, 2010 (BUSINESS WIRE) –
Emergent BioSolutions Inc. (NYSE: EBS) today announced the presentation of positive data from a Phase I dose escalation study of TRU-016 (Protocol 16007) at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida. In an oral [...]

December 15, 2010  Tags: , , , , , , ,   Posted in: American Society of Hematology, El-Hibri, Emergent BioSolutions, Non-Hodgkin lymphoma, fuad el-hibri  No Comments

Fuad El-Hibri Recognized by Vilcek Foundation

The Vilcek Foundation was established in 2000 by Jan and Marica Vilcek, immigrants from the former Czechoslovakia.  The Foundation was established with the aim of raising public awareness around immigrants’ contributions to the sciences, arts, and culture in the United States.  The Foundation’s mission was inspired [...]

December 10, 2010  Tags: , , , , , , ,   Posted in: El-Hibri, El-Hibri Peace Education Prize, Emergent BioSolutions, Peace Education, fuad el-hibri  No Comments

Fuad El-Hibri and the International Biomedical Research Alliance

The International Biomedical Research Alliance (IBRA) is a philanthropic organization that is dedicated to the support of the NIH-Oxford-Cambridge Scholars Program, which strives to establish the highest standards of excellence in training biomedical researchers, advance groundbreaking biomedical research, enrich the pool of leaders in the field, and eliminate barriers which frustrate [...]

November 13, 2010  Tags: , , , , , ,   Posted in: Biosolutions, Biothrax, El-Hibri, Emergent BioSolutions, Research and development, fuad el-hibri  No Comments

Emergent BioSolutions Completes Acquisition of Trubion Pharmaceuticals

ROCKVILLE, Md., Oct 28, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the acquisition of Trubion Pharmaceuticals, Inc., following a majority vote to approve the merger by Trubion stockholders at a special meeting conducted at Trubion’s Seattle headquarters on October 28, 2010. The acquisition [...]

November 3, 2010  Tags: , , , ,   Posted in: Business, Emergent BioSolutions, Seattle, Trubion Pharmaceuticals, fuad el-hibri  No Comments